X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (105) 105
oncology (100) 100
female (96) 96
aged (78) 78
middle aged (78) 78
index medicus (75) 75
adult (68) 68
breast cancer (49) 49
chemotherapy (46) 46
male (44) 44
cancer (37) 37
prognosis (36) 36
breast neoplasms - pathology (33) 33
metastasis (29) 29
survival (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
paclitaxel (25) 25
aged, 80 and over (24) 24
breast neoplasms - drug therapy (24) 24
antineoplastic combined chemotherapy protocols - adverse effects (23) 23
bone-marrow (22) 22
treatment outcome (21) 21
tumors (21) 21
docetaxel (20) 20
research (20) 20
research article (20) 20
lung neoplasms - drug therapy (19) 19
neoplasm staging (19) 19
care and treatment (18) 18
peripheral-blood (18) 18
breast neoplasms - blood (17) 17
expression (17) 17
neoplasm metastasis (17) 17
neoplastic cells, circulating - metabolism (17) 17
cisplatin (16) 16
adjuvant chemotherapy (15) 15
deoxycytidine - analogs & derivatives (15) 15
hematology, oncology and palliative medicine (15) 15
lung neoplasms - pathology (15) 15
survival analysis (15) 15
cancer research (14) 14
carcinoma (14) 14
carcinoma, non-small-cell lung - drug therapy (14) 14
deoxycytidine - administration & dosage (14) 14
medicine (14) 14
multivariate analysis (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
breast neoplasms - metabolism (13) 13
cell line, tumor (13) 13
circulating tumor cells (13) 13
gemcitabine (13) 13
medicine & public health (13) 13
neoplastic cells, circulating - pathology (13) 13
development and progression (12) 12
disease-free survival (12) 12
drug administration schedule (12) 12
molecular-detection (12) 12
paclitaxel - administration & dosage (12) 12
patients (12) 12
pharmacology & pharmacy (12) 12
analysis (11) 11
breast neoplasms - genetics (11) 11
carboplatin (11) 11
carcinoma, non-small-cell lung - pathology (11) 11
chemotherapy, adjuvant (11) 11
lung cancer, non-small cell (11) 11
oncology, experimental (11) 11
rna-positive cells (11) 11
survival rate (11) 11
therapy (11) 11
combination (10) 10
genetic aspects (10) 10
medical prognosis (10) 10
metastases (10) 10
mutation (10) 10
nsclc (10) 10
respiratory system (10) 10
solid tumors (10) 10
trial (10) 10
antineoplastic agents - therapeutic use (9) 9
breast neoplasms - mortality (9) 9
cancer patients (9) 9
cancer therapies (9) 9
clinical trials (9) 9
colorectal cancer (9) 9
dose-response relationship, drug (9) 9
lung cancer (9) 9
lung neoplasms - mortality (9) 9
organoplatinum compounds - administration & dosage (9) 9
oxaliplatin (9) 9
polymerase chain reaction (9) 9
polymerase-chain-reaction (9) 9
reverse transcriptase polymerase chain reaction (9) 9
taxoids - administration & dosage (9) 9
trastuzumab (9) 9
antineoplastic agents - administration & dosage (8) 8
carcinoma, non-small-cell lung - mortality (8) 8
disease (8) 8
doxorubicin (8) 8
egfr (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of immunology research, ISSN 2314-8861, 11/2014, Volume 2014, pp. 659294 - 12
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of cells with immunosuppressive properties and might confer to worse prognosis in... 
IMMUNE SUPPRESSION | INDUCE | EXPANSION | DISEASE | REGULATORY T-CELLS | DIFFERENTIATION | IMMUNOLOGY | IDENTIFICATION | CARCINOMA | SUBSET | VACCINES | Lung Neoplasms - drug therapy | Multivariate Analysis | Prognosis | Reactive Oxygen Species - metabolism | Humans | Middle Aged | Sialic Acid Binding Ig-like Lectin 3 - immunology | Male | Monocytes - metabolism | Monocytes - immunology | Lewis X Antigen - metabolism | Lipopolysaccharide Receptors - metabolism | Flow Cytometry | Nitric Oxide Synthase Type II - immunology | Myeloid Cells - immunology | Reactive Oxygen Species - immunology | Aged, 80 and over | Female | HLA-DR Antigens - metabolism | Sialic Acid Binding Ig-like Lectin 3 - metabolism | CD11b Antigen - immunology | Lewis X Antigen - immunology | Immunophenotyping | Lipopolysaccharide Receptors - immunology | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Lung Neoplasms - immunology | Myeloid Cells - metabolism | Carcinoma, Non-Small-Cell Lung - blood | Aged | HLA-DR Antigens - immunology | Lung Neoplasms - blood | CD11b Antigen - metabolism | Carcinoma, Non-Small-Cell Lung - drug therapy | Nitric Oxide Synthase Type II - metabolism | Studies | Biomedical research | Lymphocytes | Immunotherapy | Medical prognosis | T cell receptors | Metastasis | Multivariate analysis | Cancer therapies | Immune system
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 8, p. e104902
Introduction: Circulating tumor cells (CTCs) could represent a non-invasive source of cancer cells used for longitudinal monitoring of the tumoral mutation... 
HETEROGENEITY | SURVIVAL | THERAPY | PREDICT | MARKER | DNA | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | PROGRESSION-FREE | MUTATIONS | EGFR | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Mutation, Missense | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Bevacizumab | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | HCT116 Cells | Genotype | Proto-Oncogene Proteins - genetics | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplastic Cells, Circulating | Aged | Colorectal Neoplasms - pathology | Usage | Peptides | Analysis | Colorectal cancer | Development and progression | Metastasis | Drug therapy | Laboratories | Identification methods | Epithelial cells | Lung cancer | Colorectal carcinoma | Oncology | Biology | Cancer therapies | Blood | Metastases | DNA methylation | Deoxyribonucleic acid--DNA | Blood & organ donations | Tumor cells | Invasiveness | Medical treatment | Feasibility studies | Breast cancer | Patients | Medicine | Chemotherapy | Hospitals | Medical prognosis | Mutation | Codons | Prostate cancer | Peptide nucleic acids | Tumors | Cancer | Deoxyribonucleic acid
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2013, Volume 8, Issue 9, p. e74611
..., Greece Dimitris Mavroudis Affiliations Laboratory of Tumour Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece, Department of Medical... 
Lung Neoplasms - drug therapy | Multivariate Analysis | Predictive Value of Tests | Endonucleases - genetics | Copper-transporting ATPases | Humans | Middle Aged | Lung Neoplasms - pathology | Genes, myc | RNA, Messenger - metabolism | Small Cell Lung Carcinoma - drug therapy | Adult | Cation Transport Proteins - genetics | Gene Expression Regulation, Neoplastic - drug effects | Genes, Neoplasm - genetics | Lung Neoplasms - genetics | Antigens, Neoplasm - genetics | Membrane Proteins - genetics | RNA, Messenger - genetics | DNA Topoisomerases, Type I - genetics | Etoposide - pharmacology | Etoposide - therapeutic use | Treatment Outcome | Small Cell Lung Carcinoma - genetics | Cisplatin - pharmacology | Thyroid Hormones - genetics | DNA-Binding Proteins - genetics | BRCA1 Protein - genetics | Carrier Proteins - genetics | Disease-Free Survival | Small Cell Lung Carcinoma - pathology | Cisplatin - therapeutic use | DNA Topoisomerases, Type II - genetics | Adenosine Triphosphatases - genetics | Aged | Laboratories | Genes | Lung cancer | c-Myc protein | Oncology | Biology | Metastasis | Myc protein | Kinases | Cancer therapies | Proteins | Deoxyribonucleic acid--DNA | BRCA1 protein | Small cell lung carcinoma | Etoposide | Breast cancer | Radiation therapy | Gene expression | Survival | Patients | Cisplatin | Medicine | Serum levels | Studies | Pathology | Gene amplification | Chemotherapy | Hospitals | ERCC1 protein | Tumors | Cancer | Deoxyribonucleic acid | DNA
Journal Article